期刊
CURRENT HYPERTENSION REPORTS
卷 15, 期 6, 页码 531-537出版社
SPRINGER
DOI: 10.1007/s11906-013-0391-y
关键词
Uric acid; Hypertension; Chronic kidney disease; CKD; End-stage renal disease; ESRD; Cardiovascular risk; Endothelial dysfunction; Inflammation; Atherosclerosis; Arteriolosclerosis; Nephrosclerosis
Over the last decade, the biologic interference of uric acid with the cardiovascular (CV) system and the kidney has been intensively investigated, and several experimental studies in animal models and in vitro documented that hyperuricemia may trigger hypertension and incite endothelial dysfunction, vascular damage and renal disease. A substantial proportion of epidemiological studies are compatible with the hypothesis that hyperuricemia may be noxious to the CV system and the kidney as well. However, there are still no well-powered trials testing whether uric acid-lowering interventions may reduce BP or attenuate the risk for adverse CV and renal outcomes. Evidence still remains largely insufficient to recommend changes in the current policy of not prescribing uric acid-lowering drugs to individuals with asymptomatic hyperuricemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据